Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma

(2012) B. A. Walker et al.   BLOOD

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

(2012) J. B. Egan et al.   BLOOD

New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?

(2012) Ahmad Awada et al.   CANCER TREATMENT REVIEWS

Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

(2012) F. M. Ross et al.   HAEMATOLOGICA

R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study

(2011) Alberto S. Pappo et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

(2011) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma

(2011) Heribert Juergens et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome

(2011) Maria D. Begnami et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

A framework for variation discovery and genotyping using next-generation DNA sequencing data

(2011) Mark A DePristo et al.   NATURE GENETICS

Acute Mesenteric Infarction Associated with Atrial Fibrillation

(2011) Jia-Ming Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAFMutations in Hairy-Cell Leukemia

(2011) Enrico Tiacci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Many Multiple Myelomas: Making More of the Molecular Mayhem

(2011) M. Chesi et al.   Hematology-American Society of Hematology Education Program

Impressions of the myeloma landscape

(2010) P. L. Bergsagel   BLOOD

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

(2010) T. Steinbrunn et al.   BLOOD

Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585

(2010) Thorsten Stühmer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Small Is Beautiful: Insulin-Like Growth Factors and Their Role in Growth, Development, and Cancer

(2010) Robert G. Maki   JOURNAL OF CLINICAL ONCOLOGY

The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored

(2010) D. Szklarczyk et al.   NUCLEIC ACIDS RESEARCH

Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting

(2010) Jan A. Burger   SEMINARS IN CANCER BIOLOGY

The molecular characterization and clinical management of multiple myeloma in the post-genome era

(2009) Y Zhou et al.   LEUKEMIA

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

(2009) Shaji K. Kumar et al.   MAYO CLINIC PROCEEDINGS

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

(2008) A. Zollinger et al.   BLOOD

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

(2008) Mauricio Pineda-Roman et al.   BRITISH JOURNAL OF HAEMATOLOGY

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

(2008) Enrique M Ocio et al.   LANCET ONCOLOGY